Drugs / CT303
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05238532 | Jan 2022 → Feb 2023 | acute respiratory distress syndrome | GC Cell Corporation | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05258331 | Oct 2021 → Aug 2024 | psoriasis | GC Cell Corporation | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05258331 ↗ |
| Modality | Cell therapy | “CT303 Starting Dose : 1.0\*10\^6 cells/kg” NCT05238532 ↗ |
| Route | Intravenous | “Once a time, intravenous injection” NCT05238532 ↗ |